Guobang Pharma (SHSE:605507) Piotroski F-Score: 5 (As of Sep. 16, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:605507 Guobang Pharma Ltd SHSE:605507
81 GF Score
Price ¥17.76
GF Value ¥15.68
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Guobang Pharma Piotroski F-Score?

Guobang Pharma SHSE:605507 +0.17% 81 Piotroski F-Score is 5 as of Sep. 16, 2026, which is at its 10-year median of 5.00. GuruFocus rates SHSE:605507 with a GF Score™ of 81/100 and a GF Value™ of ¥15.68 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 984 Drug Manufacturers companies, Guobang Pharma ranks better than 60.87% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Guobang Pharma has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Guobang Pharma's Piotroski F-Score or its related term are showing as below:

SHSE:605507' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 5   Max: 8
Current: 5

During the past 8 years, the highest Piotroski F-Score of Guobang Pharma was 8. The lowest was 2. And the median was 5.

Guobang Pharma  (SHSE:605507) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Guobang Pharma Piotroski F-Score Related Terms


Guobang Pharma Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Guobang Pharma's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guobang Pharma Piotroski F-Score Chart

Guobang Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial 4.00 5.00 3.00 7.00 5.00

Guobang Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.00 6.00 5.00 6.00 5.00

SHSE:605507 vs ZTS: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Guobang Pharma's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guobang Pharma Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Guobang Pharma's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Guobang Pharma's Piotroski F-Score falls into.


SHSE:605507
81GF Score
Guobang Pharma Ltd SHSE:605507
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun26) TTM:Last Year (Jun25) TTM:
Net Income was 216.42390898 + 151.1629637 + 162.38731539 + 182.87148117 = ¥713 Mil.
Cash Flow from Operations was 311.26675566 + 141.73685848 + 195.09917752 + 267.95193945 = ¥916 Mil.
Revenue was 1443.60061504 + 1541.51310084 + 1520.88027795 + 1621.54826412 = ¥6,128 Mil.
Gross Profit was 368.83159493 + 341.39247821 + 331.97050505 + 377.51023211 = ¥1,420 Mil.
Average Total Assets from the begining of this year (Jun25)
to the end of this year (Jun26) was
(10821.87963485 + 10579.38283897 + 10998.84477655 + 11395.79493558 + 11398.47526208) / 5 = ¥11038.87548961 Mil.
Total Assets at the begining of this year (Jun25) was ¥10,822 Mil.
Long-Term Debt & Capital Lease Obligation was ¥177 Mil.
Total Current Assets was ¥6,471 Mil.
Total Current Liabilities was ¥2,775 Mil.
Net Income was 175.13591922 + 204.22019388 + 216.93588027 + 242.66318429 = ¥839 Mil.

Revenue was 1525.79063553 + 1472.69205545 + 1440.05593713 + 1586.22784609 = ¥6,025 Mil.
Gross Profit was 366.6320718 + 296.32297395 + 361.53626868 + 412.75562525 = ¥1,437 Mil.
Average Total Assets from the begining of last year (Jun24)
to the end of last year (Jun25) was
(10086.96128549 + 10633.38701099 + 10780.43616758 + 11114.68395654 + 10821.87963485) / 5 = ¥10687.46961109 Mil.
Total Assets at the begining of last year (Jun24) was ¥10,087 Mil.
Long-Term Debt & Capital Lease Obligation was ¥507 Mil.
Total Current Assets was ¥5,987 Mil.
Total Current Liabilities was ¥2,209 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Guobang Pharma's current Net Income (TTM) was 713. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Guobang Pharma's current Cash Flow from Operations (TTM) was 916. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun25)
=712.84566924/10821.87963485
=0.06587078

ROA (Last Year)=Net Income/Total Assets (Jun24)
=838.95517766/10086.96128549
=0.08317224

Guobang Pharma's return on assets of this year was 0.06587078. Guobang Pharma's return on assets of last year was 0.08317224. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Guobang Pharma's current Net Income (TTM) was 713. Guobang Pharma's current Cash Flow from Operations (TTM) was 916. ==> 916 > 713 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun25 to Jun26
=176.57113502/11038.87548961
=0.01599539

Gearing (Last Year: Jun25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun24 to Jun25
=507.00113502/10687.46961109
=0.04743884

Guobang Pharma's gearing of this year was 0.01599539. Guobang Pharma's gearing of last year was 0.04743884. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun26)=Total Current Assets/Total Current Liabilities
=6470.75166611/2774.80700443
=2.33196459

Current Ratio (Last Year: Jun25)=Total Current Assets/Total Current Liabilities
=5987.06129982/2208.72244065
=2.71064448

Guobang Pharma's current ratio of this year was 2.33196459. Guobang Pharma's current ratio of last year was 2.71064448. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Guobang Pharma's number of shares in issue this year was 763.018. Guobang Pharma's number of shares in issue last year was 774.186. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=1419.7048103/6127.54225795
=0.23169237

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1437.24693968/6024.7664742
=0.23855646

Guobang Pharma's gross margin of this year was 0.23169237. Guobang Pharma's gross margin of last year was 0.23855646. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun25)
=6127.54225795/10821.87963485
=0.56621793

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun24)
=6024.7664742/10086.96128549
=0.5972826

Guobang Pharma's asset turnover of this year was 0.56621793. Guobang Pharma's asset turnover of last year was 0.5972826. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+1+0+1+0+0
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Guobang Pharma has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 5 mean?
Guobang Pharma (SHSE:605507) has a Piotroski F-Score of 5 as of Sep. 16, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Guobang Pharma and its competitors. This is near median its historical median of 5.00. Over the past decade, Guobang Pharma's Piotroski F-Score has ranged from 2.00 to 8.00. According to the industry distribution chart, Guobang Pharma ranks #385 out of 984 companies in the Drug Manufacturers industry, placing it in the top 39.1%.
Is Guobang Pharma's Piotroski F-Score too high?
Guobang Pharma's current Piotroski F-Score of 5 is near median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 8.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Guobang Pharma's value of 5 is 0% at this industry median. Based on the distribution chart, Guobang Pharma ranks #385 out of 984 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Guobang Pharma has a GF Score™ of 81/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Guobang Pharma's Piotroski F-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Guobang Pharma ranks #385 out of 984 companies for Piotroski F-Score. This puts Guobang Pharma in the upper half of its industry. The industry median Piotroski F-Score is 5.00. Guobang Pharma's value of 5 is 0% at this benchmark. Historically, Guobang Pharma's own Piotroski F-Score has ranged from 2.00 to 8.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Guobang Pharma has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 984 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guobang Pharma's current Piotroski F-Score of 5 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Guobang Pharma and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guobang Pharma's current Piotroski F-Score is 5, which is near median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guobang Pharma stock overvalued right now?
Based on GuruFocus' analysis, Guobang Pharma (SHSE:605507) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥15.68, compared to a current price of ¥17.76 — trading 13.3% above its estimated fair value. The current Piotroski F-Score is 5, which is near median its 10-year median of 5.00 and 0% at the Drug Manufacturers industry median of 5.00. Guobang Pharma's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Guobang Pharma (SHSE:605507), the current Piotroski F-Score is 5 as of Sep. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Guobang Pharma (SHSE:605507) Overvalued in 2026?

Based on GuruFocus' analysis, Guobang Pharma stock appears to be overvalued. The current stock price of ¥17.76 is trading 13.3% above its estimated GF Value™ of ¥15.68. GuruFocus considers Guobang Pharma to be Modestly Overvalued.

Key valuation signals for SHSE:605507:

  • Piotroski F-Score: 5 (near median its 10-year median of 5.00)
  • GF Value™: ¥15.68 vs. price of ¥17.76 (13.3% above fair value)
  • GF Score™: 81/100 with 4 warning signs
  • Industry Position: 0% at the Drug Manufacturers median (#385 of 984)

No single metric tells the full story. See the SHSE:605507 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Guobang Pharma Business Description

Address No. 60, Xingmei Avenue, Provincial High-tech Industrial Park, Zhejiang Province, Xinchang, CHN, 312500
Guobang Pharma Ltd is engaged in the research and development, production and sales of related products in the field of medicine and animal health products.
81GF Score

Get the complete analysis for SHSE:605507

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥17.76
Price
¥15.68
GF Value